LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
|Articles|October 15, 2020
- BioPharm International-10-15-2020
- Volume 2020 eBook
- Issue 3
Regulatory and Standard Setting Organizations
Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
Advertisement
Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
Access these resources in
Articles in this issue
almost 6 years ago
Bio/Pharma Industry Works Overtime to Find COVID-19 Therapiesalmost 6 years ago
GMPs Guide COVID-19 Vaccine Manufacturingalmost 6 years ago
Viral Vector API Characterization of Product-Related Impuritiesalmost 6 years ago
Do Pharmacopoeias Inadvertently Facilitate Data Integrity Violations?almost 6 years ago
Tackling Cybersecurity Challenges in Legacy Systemsalmost 6 years ago
Enhancing Process Validation for Sterile Liquid and Freeze-Dried Formsalmost 6 years ago
Due Diligence Assessment of CMC Activitiesalmost 6 years ago
Strong Quality Culture: A How-To for Busy Managersalmost 6 years ago
Resources, Guidelines, and Guidance DocumentsAdvertisement
Related to this article
Patients suffered pyrogenic reactions before Fresenius Kabi recalled 3 contaminated batches at its 430,000-sq-ft Melrose Park, Ill., biologics plant.
FDA's new rule formally recognizes non-animal methods like organoids and AI models as valid ways to support human drug testing.
Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.
NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.
Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.
IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.
Insulin efsitora alfa-gobe (Onswik) cuts injections from 365 to 52 a year for adults with type 2 diabetes, per its new FDA approval.
Advertisement
Advertisement